Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Natalizumab in Inclusion Body Myositis
NCT02483845Phase 1Unknown
- Sponsor
- Phoenix Neurological Associates
- Start
- May 2013
- Primary completion
- Nov 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of natalizumab in inclusion body myositis (IBM), sponsored by Phoenix Neurological Associates. Primary endpoints: Degree of inflammation and types of inflammatory cells in muscle biopsies at 12 months and Manual Muscle Testing (MMT) at 12 months. Status: unknown.
02
Drugs
natalizumab
03
Conditions
inclusion body myositis (IBM)
Beyond the preview
Go deeper on NCT02483845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02483845.